Literature DB >> 8524818

Characterization of a 23-kDa protein associated with CD40.

T Morio1, S Hanissian, R S Geha.   

Abstract

CD40 is a 45-kDa glycoprotein member of the tumor necrosis factor receptor (TNFR) family expressed on B cells, thymic epithelial cells, dendritic cells, and some carcinoma cells. The unique capacity of CD40 to trigger immunoglobulin isotype switching is dependent on the activation of protein-tyrosine kinases, yet CD40 possesses no kinase domain and no known consensus sequences for binding to protein-tyrosine kinases. Recently, an intracellular protein (CD40bp/LAP-1/CRAF-1) which belongs to the family of TNFR-associated proteins was reported to associate with CD40. We describe a 23-kDa cell surface protein (p23) which is specifically associated with CD40 on B cells and on urinary bladder transitional carcinoma cells. Protein microsequencing revealed that p23 shows no homology to any known protein. A rabbit antibody raised against a peptide derived from p23 recognized a 23-kDa protein in CD40 immunoprecipitates. In contrast to CD40bp/LAP-1/CRAF-1, p23 was not associated with TNFR p80 (CD120b). These findings suggest that p23 is a novel member of the CD40 receptor complex.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8524818      PMCID: PMC40456          DOI: 10.1073/pnas.92.25.11633

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  21 in total

1.  Involvement of CRAF1, a relative of TRAF, in CD40 signaling.

Authors:  G Cheng; A M Cleary; Z S Ye; D I Hong; S Lederman; D Baltimore
Journal:  Science       Date:  1995-03-10       Impact factor: 47.728

2.  A novel RING finger protein interacts with the cytoplasmic domain of CD40.

Authors:  H M Hu; K O'Rourke; M S Boguski; V M Dixit
Journal:  J Biol Chem       Date:  1994-12-02       Impact factor: 5.157

3.  The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family.

Authors:  G Mosialos; M Birkenbach; R Yalamanchili; T VanArsdale; C Ware; E Kieff
Journal:  Cell       Date:  1995-02-10       Impact factor: 41.582

4.  T lymphocyte T cell-B cell-activating molecule/CD40-L molecules induce normal B cells or chronic lymphocytic leukemia B cells to express CD80 (B7/BB-1) and enhance their costimulatory activity.

Authors:  M J Yellin; J Sinning; L R Covey; W Sherman; J J Lee; E Glickman-Nir; K C Sippel; J Rogers; A M Cleary; M Parker
Journal:  J Immunol       Date:  1994-07-15       Impact factor: 5.422

5.  The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation.

Authors:  T Kawabe; T Naka; K Yoshida; T Tanaka; H Fujiwara; S Suematsu; N Yoshida; T Kishimoto; H Kikutani
Journal:  Immunity       Date:  1994-06       Impact factor: 31.745

6.  CD40-deficient mice generated by recombination-activating gene-2-deficient blastocyst complementation.

Authors:  E Castigli; F W Alt; L Davidson; A Bottaro; E Mizoguchi; A K Bhan; R S Geha
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-06       Impact factor: 11.205

7.  Role of protein tyrosine kinases in CD40/interleukin-4-mediated isotype switching to IgE.

Authors:  R K Loh; H H Jabara; C L Ren; S M Fu; R S Geha
Journal:  J Allergy Clin Immunol       Date:  1994-10       Impact factor: 10.793

8.  CD40 signaling pathway: anti-CD40 monoclonal antibody induces rapid dephosphorylation and phosphorylation of tyrosine-phosphorylated proteins including protein tyrosine kinase Lyn, Fyn, and Syk and the appearance of a 28-kD tyrosine phosphorylated protein.

Authors:  M Faris; F Gaskin; J T Parsons; S M Fu
Journal:  J Exp Med       Date:  1994-06-01       Impact factor: 14.307

9.  Physical and functional association of the high affinity immunoglobulin G receptor (Fc gamma RI) with the kinases Hck and Lyn.

Authors:  A V Wang; P R Scholl; R S Geha
Journal:  J Exp Med       Date:  1994-09-01       Impact factor: 14.307

10.  gp39-CD40 interactions are essential for germinal center formation and the development of B cell memory.

Authors:  T M Foy; J D Laman; J A Ledbetter; A Aruffo; E Claassen; R J Noelle
Journal:  J Exp Med       Date:  1994-07-01       Impact factor: 14.307

View more
  6 in total

1.  CD40 signaling in human dendritic cells is initiated within membrane rafts.

Authors:  P O Vidalain; O Azocar; C Servet-Delprat; C Rabourdin-Combe; D Gerlier; S Manié
Journal:  EMBO J       Date:  2000-07-03       Impact factor: 11.598

2.  Low-grade B cell lymphomas of mucosa-associated lymphoid tissue (MALT-type) require CD40-mediated signaling and Th2-type cytokines for in vitro growth and differentiation.

Authors:  A Greiner; C Knörr; Y Qin; W Sebald; A Schimpl; J Banchereau; H K Müller-Hermelink
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

3.  The in vivo function of a noncanonical TRAF2-binding domain in the C-terminus of CD40 in driving B-cell growth and differentiation.

Authors:  Li-Fan Lu; Cory L Ahonen; Evan F Lind; Vanitha S Raman; W James Cook; Ling-Li Lin; Randolph J Noelle
Journal:  Blood       Date:  2007-03-14       Impact factor: 22.113

Review 4.  The hyper-IgM (HIM) syndrome.

Authors:  N Ramesh; M Seki; L D Notarangelo; R S Geha
Journal:  Springer Semin Immunopathol       Date:  1998

5.  Phenotypic variations between affected siblings with ataxia-telangiectasia: ataxia-telangiectasia in Japan.

Authors:  Tomohiro Morio; Naomi Takahashi; Fumiaki Watanabe; Fumiko Honda; Masaki Sato; Masatoshi Takagi; Ken-Ichi Imadome; Toshio Miyawaki; Domenico Delia; Kotoka Nakamura; Richard A Gatti; Shuki Mizutani
Journal:  Int J Hematol       Date:  2009-08-25       Impact factor: 2.490

6.  Single nucleotide polymorphisms in the CD40 gene associate with the disease susceptibility and severity in knee osteoarthritis in the Chinese Han population: a case-control study.

Authors:  Zhen-Han Deng; Ming-Hua Sun; Yu-Sheng Li; Wei Luo; Fang-Jie Zhang; Jian Tian; Ping Wu; Wen-Feng Xiao
Journal:  BMC Musculoskelet Disord       Date:  2017-03-21       Impact factor: 2.362

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.